{"nctId":"NCT02106832","briefTitle":"Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","startDateStruct":{"date":"2014-04-30","type":"ACTUAL"},"conditions":["Bronchiectasis"],"count":521,"armGroups":[{"label":"Ciprofloxacin DPI 28 Days on/off (Cipro 28)","type":"EXPERIMENTAL","interventionNames":["Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation"]},{"label":"Ciprofloxacin DPI 14 Days on/off (Cipro 14)","type":"EXPERIMENTAL","interventionNames":["Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation"]},{"label":"Placebo 28 Days on/off (Placebo 28)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Placebo 14 Days on/off (Placebo 14)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ciprofloxacin (BAYQ3939) dry powder for inhalation","otherNames":[]},{"name":"Ciprofloxacin (BAYQ3939) dry powder for inhalation","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a proven and documented diagnosis of non CF idiopathic or post infectious bronchiectasis\n* Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks\n\nExclusion Criteria:\n\n* Forced expiratory volume in 1 second (FEV1) \\<30% or \\>90% predicted\n* Active allergic bronchopulmonary aspergillosis\n* Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis\n* Primary diagnosis of Chronic obstructive pulmonary disease (COPD)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo","description":"Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms.","paramType":"MEDIAN","dispersionType":"99.9% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks","description":"For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks","description":"For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)","description":"Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"31.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)","description":"The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.92","spread":"21.06"},{"groupId":"OG001","value":"-9.02","spread":"20.10"},{"groupId":"OG002","value":"-2.91","spread":"24.48"},{"groupId":"OG003","value":"-11.50","spread":"18.54"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)","description":"New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"67.6","spread":null},{"groupId":"OG002","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)","description":"The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.57","spread":"17.49"},{"groupId":"OG001","value":"10.90","spread":"18.07"},{"groupId":"OG002","value":"7.08","spread":"17.00"},{"groupId":"OG003","value":"10.70","spread":"15.58"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)","description":"FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"0.336"},{"groupId":"OG001","value":"-0.037","spread":"0.287"},{"groupId":"OG002","value":"-0.038","spread":"0.272"},{"groupId":"OG003","value":"0.037","spread":"0.299"}]}]}]},{"type":"PRIMARY","title":"Time to First Exacerbation Event Within 48 Weeks - Cipro 14 vs. Pooled Placebo","description":"Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms.","paramType":"MEDIAN","dispersionType":"95.1% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":171},"commonTop":["Haemoptysis","Nasopharyngitis","Headache","Upper respiratory tract infection","Cough"]}}}